Insulet makes the Omnipod, a tubeless insulin pump worn directly on the skin and controlled from a phone. The pod is discarded and replaced every few days, which turns a medical device company into a recurring consumables business with pharmacy distribution. Automated dosing software that talks to continuous glucose monitors moves the product toward an artificial pancreas. Type 1 diabetes is the base market and the far larger type 2 population is the expansion story. Insulet was founded in 2000 and remains focused on this single franchise.